Core Viewpoint - The Phase I clinical trial of LZ901 vaccine conducted in the United States has been successfully completed, demonstrating good safety and immunogenicity in both high-dose and low-dose groups compared to the placebo group, laying the foundation for subsequent clinical research [1] Group 1: Clinical Trial Results - The Phase I clinical trial primarily aimed to verify the safety of the vaccine, with only the low-dose group showing mild adverse reactions related to the vaccine at a rate of 4.35%, while no adverse reactions were reported in the high-dose and placebo groups [1] - Both high-dose and low-dose groups of the LZ901 vaccine exhibited good safety and immunogenicity compared to the placebo group [1] Group 2: Product Development - LZ901 is a self-developed recombinant shingles vaccine by the company, targeting the prevention of shingles and related complications in adults aged 40 and above [1] - The Phase III clinical trial of LZ901 in China has met its clinical preset goals and achieved expected clinical results [1] - As of the announcement date, the biological product license application for LZ901 has been accepted by the National Medical Products Administration of China and is currently under evaluation [1]
绿竹生物-B于美国成功完成LZ901的I期临床试验